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The renal community owes Dr. Frank Gotch a great
debt for the contributions that he has made to clarify the
relationship between urea clearance and the dose of di-
alysis. With John Sargent he developed the mathematical
approach to hemodialysis (1). In his seminal publication
he re-analyzed data of the National Cooperative Dialysis
Study to establish the association between the theoreti-
cally derived Kt/V for urea and clinical outcomes (2).
Although diffusion equations are well understood and
are used in many fields of science, Dr. Gotch’s persistent
and tireless efforts to identify and quantitate the specific
aspects of this process in dialysis through formal kinetic
modeling, yielding additionally the protein catabolic rate
(PCR) (3), have been extremely valuable to both patients
and clinicians alike. The continuing measurement of Kt/
Vurea in every dialysis unit is a lasting tribute to Dr.
Gotch’s contributions.
Accurate measurement of the dose of dialysis is im-
portant in part because of its relationship to patient out-
comes and to the cost of dialysis. Further, the concepts
underlying the dose of episodic hemodialysis, pioneered
by Dr. Gotch, are of practical importance in understand-
ing the role of residual renal function and in quantit-
ateing the dose of continuous dialytic procedures. Kt/V
has been found to be one of the key modifiable compo-
nents of the practice of hemodialysis.
Several recent presentations have identified nutritional
factors as among the strongest predictors of end-stage
renal disease (ESRD) patient mortality (4–6). There is
no single omnibus measure of patient nutritional status,
but several surrogates, including clinical assessment,
higher serum creatinine, albumin, prealbumin, patient
weight (volume or total body water), body mass index
(BMI), and urea generation (or PCR), have been shown
to be strong correlates of lower patient mortality (4–9).
In an analysis from the United States Renal Data System
(USRDS) Case Mix Adequacy Study, we found that
among the four most important predicators of mortality,
three were indicators of nutrition (BMI, serum albumin
and serum creatinine), with age being the strongest pre-
dictor. Comorbid conditions appeared to have a lesser
predictive power. Figure 1 shows several patient charac-
teristics, ordered by the relative risk (RR) per standard
deviation change for each characteristic. The use of RR
per standard deviation makes the ordering more mean-
ingful by reflecting the RR for a “typical” change in each
factor. The importance of nutritional status emphasizes
the fact that single-minded attention to dialysis dose is
not sufficient for achieving good patient outcomes.
However, the importance of nutrition should not blind
us to the importance of the dose of dialysis. It is well
known that it is essential to maintain an adequate dose of
dialysis for the ESRD patient, since, without dialysis,
death is an early and certain outcome. Several recent
observational studies have tried to identify the shape of
the relationship of dose of dialysis to mortality and have
identified an apparent flattening of the relationship with
mortality risk as the dose of dialysis is increased double
pool Kt/V (eKt/V) above 1.1 or a single pool Kt/V (spKt/
V) of 1.3 (10–12). One of the major objectives of the
current HEMO trial (13) is the evaluation of the effect of
raising the dose of dialysis above the current common
practice in the United States.
We strongly suggest that it is crucial to manageboth
the dose of dialysis and patient nutrition in the treatment
of ESRD patients. Here, we examine the links between
these two factors, consider in broad terms how dose
should be measured, and consider the problem of iden-
tifying the optimal dose of dialysis.
Links Between Dose and Nutrition
Lindsey hypothesized that higher Kt/V would lead to
better nutrition in ESRD patients (14). Several observa-
tional studies have yielded conflicting data in favor of or
against this hypothesis. This hypothesis will be difficult
to establish without a clinical trial because dose of di-
alysis and nutritional status are linked by dialysis prac-
tices and by mathematical links between their measures
as described below.
The commonly used empirical measures of dose of
dialysis and nutritional status are both based on pre- and
post-dialysis measures of urea concentration. In practice,
Kt/V often is not measured through the components, K,
t, and V, but is instead inferred based upon measure-
ments of pre- and post-dialysis blood urea nitrogen
(BUN) concentrations (15). The PCR is a fundamental
measure of protein nutrition, and it is also estimated in-
directly through the difference between post- and pre-
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dialysis BUN measures. This mathematical link has the
potential to cause the observed measured values of Kt/V
and PCR to be associated, even if there were no asso-
ciation between the true values of these factors, because
the errors in measuring BUN are propagated to both
Kt/V and PCR. This mathematical link, driven by varia-
tions (errors) in pre- and post-dialysis BUN measure-
ments, leads to a spurious positive association between
the dose of dialysis and PCR.
Higher dose of dialysis is associated with smaller pa-
tient volume because of the current dosing practices in
the United States (9, 16). That is, with current dialysis
practice in the United States, Kt is not always prescribed
in proportion to patient volume, so that larger patients
receive lower values of Kt/V on average. This associa-
tion is seen for other measures related to patient volume,
including weight and body mass index (9). This obser-
vation leads to a negative association between the dose
of dialysis and body size, which is a surrogate for nutri-
tional status and makes it difficult to discern a causal
relationship between elevating the dose of dialysis and
better nutritional status.
While these links might make it hard to disentangle
the separate effects of nutrition and dose on patient mor-
tality, they should not prevent us from recognizing their
separate effects nor divert us from trying to separate
them empirically. Perhaps the HEMO trial can shed more
light on this question.
Measuring Dialysis Dose and the Choice of
“Optimal” Dose
Most standard measures of dose are related to the frac-
tional reduction in pre and post dialysis urea concentra-
tions. Dr. Gotch helped pioneer our understanding of the
relationship between the components of dialysis (K and
t) and urea levels. Kt/V is uniquely able to link the pre-
scription of K and t to the outcome of reduced urea
concentration, depending on the urea distribution space
(V).
However, urea reduction is not the ultimate goal of
dialysis. Urea is unlikely to be the most important toxin
removed by dialysis. However, both empirical associa-
tions and logic support the concept that the concentration
of urea is a good surrogate for the effects of toxins in the
blood (particularly from protein metabolism) and ex-
plains the higher mortality seen with lower Kt/Vurea. De-
spite its importance in explaining patient mortality, the
measurement of Kt/Vurea was originally conceived as a
measure of dialysis dose, though analyzes by Gotch and
Sargent (2) pointed out that it also predicted patient out-
comes. There is evidence for a similar relationship that
Kt/V of middle molecules modifies mortality risk inde-
pendent of Kt/Vurea (17).
Empirical studies have indicated that there may be
reduced benefits to elevating the dose of dialysis much
above spKt/V4 1.3 (eKt/V4 1.1). The optimal dose of
dialysis can be defined as being the dose above which
little if any improvement in patient outcomes can be
observed. Identification of the optimal dose of dialysis,
then, is a simple matter of studying the dose response
relationship between mortality and dose. Unfortunately,
dose–response relationships are difficult to quantitate
with the level of precision needed for establishing an
optimal dose of dialysis. Specifically, it requires a sub-
stantial amount of empirical evidence to identify the dose
above which there is no benefit. Further, the relationship
of patient size and other characteristics to mortality
makes it plausible that this dose may need to be deter-
mined separately for different patient subgroups.
Recently, it has been proposed that the optimal dose of
dialysis may vary by patient group (18) and can be based
on Kt and gender, rather than upon Kt/V. As Dr. Lowrie
has pointed out, it would not be good medical practice to
reduce the level of dialysis delivered to a patient, whose
volume decreases due to worsening nutritional status,
even though this practice would be a logical approach if
Kt/V alone were considered as the criterion for choosing
the optimal dose of dialysis. Measuring the dose by Kt
would not lead to such an inappropriate practice since
patients who lose weight (volume) would continue to
receive the same level of dialysis. We wholeheartedly
agree that Kt/V should not be reduced on the basis of
reduction in patient volume. However, we are concerned
that a failure to account for patient size when choosing
the dose of dialysis also ignores the basic relationship,
pioneered by Dr. Gotch, between urea concentrations
and dose of dialysis. In particular, we hope that the di-
alysis community does not become so enamored with the
ease of prescriptions based on K and t alone that the
FIG. 1. Mortality RR per 1 SD change in
patient characteristics.
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measurement of pre- and post-BUN (or other toxin) con-
centrations is ignored.
There are a variety of approaches to measuring dose
that would avoid the problem of reducing the dose for
patients whose volume decreases. For example, prescrip-
tion on the basis of an ideal (rather than current) patient
volume may prove to be a useful concept. We should not
confuse two different objectives: choosing a good mea-
sure for the dose of dialysis, and choosing the optimal
level of the dose of dialysis. Kt/V is a good measure of
the dose of dialysis, despite the fact that it leads to in-
appropriate dosing practices when patient volume
changes. This is akin to recognizing that degrees Kelvin
is an excellent measure of temperature despite the fact
that it does not explain the boiling point of water at
different altitudes.
To reiterate, we believe that the optimal dose of di-
alysis should be based on empirical evidence. This evi-
dence requires careful calibration of the relationship be-
tween dose of dialysis and patient outcomes, especially
mortality.
Identification of the Optimal Dose of Dialysis
It is clear that patient condition, including nutritional
status, should be considered when treating ESRD pa-
tients. In view of the known association between mor-
tality and patient size, it is plausible that nutrition should
be considered when prescribing the dose of dialysis for a
patient. We believe that the selection of an optimal di-
alysis dose is largely an empirical question that does not
depend upon whether one uses Kt/V or Kt to measure
dose. In fact, for a given patient size (volume), Kt and
Kt/V are proportional measures of dialysis dose, and it
does not matter which is used as the basis for choosing a
dose level.
Figure 2 shows the schematic relationship between
mortality and Kt/V for patients of differing size (nutri-
tional status). The higher mortality shown for smaller
patients, particularly lower BMI, has been documented
by several studies (6, 9). What is not accurately known,
is the dose above which the mortality relationship is
relatively flat. Hypothesis A shows no survival benefit
above a certain Kt/V that is independent of patient size,
whereas hypothesis B assumes benefits from relatively
higher Kt/V for smaller with an earlier leveling off for
larger patients. It will be difficult to distinguish between
he hypothetical relationships A and B shown for small
patients, without data for thousands of patients.
The answer to this question can only be based on
substantial experience with mortality for a wide variety
of types of patients. The USRDS is in a unique position
to address this question. Serial measures of the dialysis
dose are now being routinely collected for all dialysis
patients as requested by HCFA through the ESRD Net-
works. Follow-up of these patients will allow identifica-
tion of the relationship between the dose of dialysis and
patient outcomes, including both mortality and hospital-
ization and assessment by patient groups. This level of
detailed data can help to answer the specific question by
type of patient of how much dialysis is needed to achieve
the optimal outcome.
Conclusion
Clinical experience and logic indicates that both nu-
tritional status and the dose of dialysis, can be modified
by the clinical practiceindependentof one another. In
view of their importance to patient survival, both need to
be measured in a standardized fashion. Such standard-
ization has been recommended by DOQI (19). Both fac-
tors need to be studied to determine levels of optimiza-
tion while considering other issues such as cost-
effectiveness.
With the recent addition of the dose of dialysis to the
data routinely collected by the HCFA, the USRDS will
offer a potential resource for the identification of such
optimal doses, for different patient subgroups. This ap-
proach is a return to Dr. Gotch’s focus on empiricism,
which should remain as the highest test of all for our
efforts at deductive reasoning.
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